

NCIC Clinical Trials Group

Abstracts to be Presented at the 34th Annual San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Center, San Antonio, Texas

December 6-10, 2011

Wednesday, December 7

Poster Session 1 – Exhibit Halls A-B - 5:00 pm to 7:00 pm

Prognosis/Response Predictions: Response Predictions – I

MA.5 – PB Hertel (P1-06-07)

TIMP-1 in Combination with HER2 and TOP2A for Prediction of Benefit from Adjuvant Anthracyclines in High Risk Breast Cancer Patients

MA.12 – J-AW Chapman (P1-06-08)

Effect of Treatment Emergent Symptoms on Relapse Free Survival: NCIC CTG MA.12 a Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women in Early Breast Cancer

Thursday, December 8

Poster Session 2 – Exhibit Halls A-B - 7:00 am to 9:00 am

Prognosis/Response Predictions:
Prognostic Factors and Biomarkers – Clinical - I

MA.5 – N Bouganim (P2-12-23)

How Should We Assess Tumour Size (T Stage) in Patients with Multicentric/Multifocal Breast Cancer? Results from the NCIC CTG MA.5 Randomized Trial of CEF vs. CMF in Pre-Menopausal Women with Node Positive Breast Cancer

MA.12 – JF Hilton (P2-12-27)

Simply Adding Together the Diameters of Tumor Foci in Patients with Multicentric or Multifocal Disease Does Not Add Any Additional Prognostic Information: An Analysis from NCIC CTG MA.12 Randomized Placebo-Controlled Trial of Tamoxifen after Adjuvant Chemotherapy in Pre-Menopausal Women with Early Breast Cancer

MA.14 – V Bramwell (P2-12-28)

Studies of a Malignancy-Associated Protein, Osteopontin, in NCIC CTG MA.14, a Randomized Trial of Tamoxifen Versus Combined Tamoxifen and Octreotide LAR in Adjuvant Treatment of Women with Early Breast Cancer

Epidemiology, Risk, and Prevention: Ethnic/Racial Aspects

MA.27 – B Moy (P2-14-02)

NCIC CTG MA.27: Clinical Tolerability and Overall Survival of Racial and Ethnic Minority Women on Aromatase Inhibitor Therapy

NCIC Clinical Trials Group

Abstracts to be Presented at the 34th Annual San Antonio Breast Cancer Symposium

Henry B. Gonzalez Convention Center, San Antonio, Texas

December 6-10, 2011

Friday, December 9

Poster Session 4 – Exhibit Halls A-B - 7:00 am to 9:00 am

Epidemiology, Risk, and Prevention - Other

MAP.3B – PE Goss (P4-11-13)

Influence of Two Years of Exemestane on Bone Mineral Density in Postmenopausal Women at Increased Risk of Developing Breast Cancer; a Companion Study to the NCIC CTG MAP.3 Trial

Poster Session 5 – Exhibit Halls A-B - 5:00 pm to 7:00 pm

Prognosis/Response Predictions:
Prognostic and Predictive Factors - Other

MA: 5 12 14 21 27 - B Dong (P5-14-01)

Differences in Efficacy by Assessment Method: NCIC CTG Adjuvant Breast Cancer Trials MA.5, MA.12, MA.14, MA.21, MA.27 Meta-Analysis

General Session 6 – Exhibit Hall D - 3:15 pm to 5:00 pm

MAP.3 –E Maunsell (3:15 pm) (S6-1)

(H Richardson presenting)

Menopause-specific and health-related qualities of life among postmenopausal women taking exemestane for prevention of breast cancer: Results from the NCIC CTG MAP.3 placebo-controlled randomized controlled trial

MA.27 - LI Wagner (3:30 pm) (S6-2)

Patient-reported predictors of early treatment discontinuation: NCIC JMA.27/E1Z03 quality of life study of postmenopausal women with primary breast cancer randomized to exemestane or anastrozole